论文部分内容阅读
目的 探讨p2 1ras、p53蛋白和增殖细胞核抗原 (proliferatingcellnuclearantigen ,PCNA)在胰腺癌发生、发展中的作用和临床意义。方法 应用免疫组化法对 30例胰腺癌 ,3例正常胰腺组织中的ras基因产物p2 1、p53蛋白和PCNA进行检测 ,并结合临床资料分析。结果 胰腺癌中p2 1、p53蛋白表达正相关 ,阳性表达率分别为 75%、53 33% ;PCNA阳性表达率为 4 3 39%±17 99% ,并随胰腺癌恶性度的增加而增加 ,与预后、p53表达相关 (P <0 0 5) ,与淋巴结转移、神经侵润及肿瘤大小无关 (P >0 0 5)。结论 胰腺癌的发生发展过程是多种癌基因协同作用的结果 ;PCNA可作为判定胰腺癌恶性程度及预后的一项指标。
Objective To investigate the role and clinical significance of p21ras, p53 protein and proliferating cell nuclear antigen (PCNA) in the development and progression of pancreatic cancer. Methods Immunohistochemical method was used to detect ras gene product p21, p53 protein and PCNA in 30 cases of pancreatic cancer and 3 cases of normal pancreas, combined with clinical data analysis. Results The expression of p21 and p53 protein was positively correlated in pancreatic cancer, the positive expression rates were 75% and 53 33%, respectively; the positive rate of PCNA was 4 3 39%±17 99%, which increased with the increase of malignant degree of pancreatic cancer. It was associated with prognosis and p53 expression (P < 0.05) and was not associated with lymph node metastasis, neural invasion, and tumor size (P > 0.05). Conclusion The occurrence and development of pancreatic cancer is the result of the synergistic effect of various oncogenes; PCNA can be used as an index to determine the malignancy and prognosis of pancreatic cancer.